Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Genome sequencing of therapy-related acute myeloid leukaemia (t-AML) has revealed that these malignancies do not have more mutations thande novo AML, and that TP53mutations, which are common in t-AML, are likely to be present before treatment with chemotherapy and expand following treatment.
